Loading...
Loading...
Analysts at Morgan Stanley initiated coverage on
Horizon Pharma PLCHZNP with a Overweight rating.
The target price for Horizon Pharma is set to $38.
Horizon Pharma shares have gained 116.45 percent over the past 52 weeks, while the S&P 500 index has surged 9.07 percent in the same period.
Horizon Pharma shares rose 0.41 percent to $31.97 in after-hours trading.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in